Stine U. Mikkelsen

Copenhagen, DK 
Clinical Trials:Currently Recruiting for 1 Trial
Copenhagen, DK 

Overview

Stine Mikkelsen practices practicing medicine in Copenhagen, Denmark.

Their clinical expertise encompasses Myelodysplastic Syndrome (MDS), Polycythemia Vera, Myelofibrosis, and Chronic Myelomonocytic Leukemia (CMML).

They are actively involved in clinical research, co-authoring 8 peer reviewed articles and participating in 2 clinical trials.

Locations

Copenhagen, Denmark
Other Locations
Esbjerg, 6700, Denmark
Roskilde, Denmark

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Combining Active and Passive DNA Hypomethylation: A Randomized, Placebo-Controlled Phase II Study of the Efficacy and Safety of Oral Vitamin C in Combination With Azacitidine in Patients With Higher-Risk MDS, CMML-2 or Low-Blast Count AML
Combining Active and Passive DNA Hypomethylation: A Randomized, Placebo-Controlled Phase II Study of the Efficacy and Safety of Oral Vitamin C in Combination With Azacitidine in Patients With Higher-Risk MDS, CMML-2 or Low-Blast Count AML
Enrollment Status: Recruiting
Publish Date: April 17, 2024
Intervention Type: Dietary supplement
Study Phase: Phase 2
Epigenetics, Vitamin C, and Abnormal Hematopoiesis - Role of Vitamin C in Epigenetic Regulation in Hematopoiesis Sub-Study on CCUS, Low-Risk MDS, and CMML-0/1
Epigenetics, Vitamin C, and Abnormal Hematopoiesis - Role of Vitamin C in Epigenetic Regulation in Hematopoiesis Sub-Study on CCUS, Low-Risk MDS, and CMML-0/1
Enrollment Status: Active_not_recruiting
Publish Date: April 17, 2024
Intervention Type: Other, Dietary supplement
Study Phase: Not Applicable
View 1 Less Clinical Trial

8 Total Publications

The risk of myelodysplastic syndrome and acute myeloid leukemia by metformin use and type 2 diabetes status - a Danish nation-wide cohort study.
The risk of myelodysplastic syndrome and acute myeloid leukemia by metformin use and type 2 diabetes status - a Danish nation-wide cohort study.
Journal: Acta oncologica (Stockholm, Sweden)
Published: November 04, 2024

Frequently Asked Questions about Stine U. Mikkelsen

Is Stine U. Mikkelsen a top-rated expert for Myelodysplastic Syndrome (MDS)?

MediFind is an objective health platform that identifies experts based on real-world data. Stine U. Mikkelsen is classified as an Experienced expert for Myelodysplastic Syndrome (MDS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Stine U. Mikkelsen participate in research or clinical trials?

Yes. Stine U. Mikkelsen has published 8 articles and abstracts on conditions like Myelodysplastic Syndrome (MDS). You can view a list of Stine U. Mikkelsen's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mikkelsen's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile